Replies to post #5406 on GTC Biotherapeutics (fka GTCB)

[ThomasS]

Are we certain that they are speaking of an ATRYN USA partner?

[n4807g]

I'm encouraged. Appears as though they expect the partnership to be finalized soon. Great step in the right direction.

[ThomasS]

"...it looks like GTC expects the amount to be received in 4Q07 from the US ATryn partner to be in the $6-8M range. The key to the economics of the partnership deal will of course be the clinical and regulatory milestone payments, particularly in the DIC indication."

Upon further reflection, I feel these milestones may be quite large. I've assumed already here that the "middle-ground" for negotiations is huge milestones with sub-optimal royalties and little upfront cash. But, this requires nice milestone payments, which may be larger than even I had assumed.

I'm excited that we may know within the next 30 days... and it's an interesting negotiating dilemma for GTC, although all positive options.

[DewDiligence]

GTC’s current cash balance is in the neighborhood of $20M less whatever has been spent on operations during 2008 to date. This includes the $6M from today’s financing.

(The old guidance of $20-22M in cash as of 12/31/07 included $6-8 from a partnership up-front payment.)